Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11891801 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Canine atopic dermatitis: An evolving understanding.
Can Vet J
March 2025
Dr. Bajwa is a Board-certified veterinary dermatologist, VETDERM Veterinary Dermatology & Ear Referral Medical Clinic, Surrey, British Columbia.
Evaluation of filaggrin 2 expression in dogs with atopic dermatitis before and after oclacitinib maleate administration.
Vet Dermatol
March 2025
Department of Veterinary Medicine, School of Medicine and Life Sciences, Pontifical Catholic University of Paraná, Curitiba, PR, Brazil.
Background: Canine atopic dermatitis (cAD) is a chronic, inflammatory, multifactorial and pruritic disease. The presence of skin barrier impairment (e.g.
View Article and Find Full Text PDFAntimicrobial activity of ear cleanser products against biofilm and planktonic phases of Staphylococcus spp. and Pseudomonas spp. isolated from canine skin and ear infections.
BMC Vet Res
March 2025
Centre for Oral Immunobiology and Regenerative Medicine, Institute of Dentistry, Queen Mary University of London, Blizard Building, 4 Newark Street, London, E1 2AT, UK.
Background: Staphylococcus spp., and Pseudomonas spp., including multidrug resistant staphylococci are frequent isolates from canine otitis externa and atopic dermatitis.
View Article and Find Full Text PDFSafety of the Selective JAK1 Inhibitor Oclacitinib in Dogs.
J Vet Pharmacol Ther
February 2025
Zoetis, Parsippany-Troy Hills, New Jersey, USA.
Apoquel(oclacitinib maleate) as a film-coated tablet, a selective Janus kinase (JAK)1 inhibitor, was approved by the United States Food and Drug Administration (FDA) in 2013 for the control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. The goal of this review is to describe the safety of oclacitinib in dogs based on data from investigational laboratory and field studies, independent directed studies, and an extensive postmarketing pharmacovigilance (PV) surveillance program. The safety of oclacitinib has been extensively evaluated in investigational and independent studies.
View Article and Find Full Text PDFTherapeutic effect of long-interval repeated subcutaneous administration of canine amniotic membrane-derived mesenchymal stem cells in atopic dermatitis mouse model.
BMC Vet Res
February 2025
The Research Institute for Veterinary Science, College of Veterinary Medicine, Seoul National University, Seoul, 08826, Republic of Korea.
Atopic dermatitis (AD) is a chronic and inflammatory disease. According to a recent study, administration of canine MSCs is a potential therapy for immunological diseases. However, most related studies involve short-term experiments and acute atopic dermatitis animal models.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!